Abstract-Despite its simple appearance, bone is a complex and dynamic tissue that is remodelled continuously. Bone remodelling is a delicate process that is essentially made of two types of cells: osteoclasts, that digest and remove old bone, and osteoblasts, that create new bone. The bone microenvironment is rich in nutrients and proteins, and hence it is not surprising that the bone is an usual place for tumor appearance. From the moment in which a tumor is established, it starts to deregulate the healthy balance between osteoclasts and osteoblasts, accelerating the bone resorption process, so that it can spread to other organs. Furthermore, the deregulated balance will cause the bone mass density to decrease, resulting in another kind of bone diseases. This paper starts by reviewing the mathematical model for tumor growth as well as the pharmacokinetics and pharmacodynamics models of the drug, so that the therapy can be as close as possible to reality. Then, the Nonlinear Model Predictive Control algorithm (NMPC) is used to find the optimal drug dose, in order to reduce the tumor density. An exponential reference signal is used in NMPC to produce smaller tracking errors with respect to a reference that drives the tumor size to a vanishing value, and the Recursive Least Squares method is used to learn the parameters of the tumor growth model, in order to obtain an adaptive NMPC strategy. Finally, this control strategy is applied to a state-of-theart bone microenvironment model used in cancer research, to schedule a therapy for reducing tumor density. Simulations in MATLAB show that the tumor is eliminated and the bone mass is recovered in a period of five years, assuming model validity.
I. INTRODUCTION A. Motivation and Literature Review
A wide range of diseases that have in common an unusual and unnecessary cell reproduction beyond the organism needs are called cancer. This uncontrolled proliferation provokes the formation of a cellular mass called tumor. The bone microenvironment provides a fertile soil for cancer cells. The reciprocal interaction between tumor and bone cells, known as vicious cycle, supports the establishment and orchestrates the expansion of malignant tumors in the bone. The therapy to repress cancer growth has collateral toxic effects that affect the patient. To study that interaction, several studies were performed recently, using mathematical models and optimization solvers, allowing a deeper understanding and control of the tumor growth [1] - [10] . Indeed some of those studies have used Model Predictive Control (MPC) to compute an optimal therapeutic schedule. In [7] an optimal chemotherapy dose is found by solving a convex optimization problem based on linear matrix inequalities; in [8] it is shown that, even when the system states are not fully directly measurable and there are mismatches in the model parameters, MPC still provides an useful schedule for cancer treatment; in [9] MPC is used to provide a chemotherapy schedule for mice with breast cancer.
It has been assumed in many researches related to diseases that it is possible to directly control the effect of a drug on the target. The effect of the body has on the drug and the effect that the drug has on the body is called pharmacokinetics (PK) and pharmacodynamics (PD), respectively. After the administration of a drug there are natural processes, such as solubility, distribution, metabolism and elimination, that affect the amount of drug concentration that reaches the target organ [14] . Studies [12] and [14] suggest mathematical models to represent those interactions. Resistance to drugs is a natural process of the human body and is a major problem in cancer therapies [16] . In [12] a drug resistance model in the treatment of HIV is presented, based on the amount of drug concentration present in the bloodstream.
Bone marrow cancer is a common type of cancer that may be the result of metastasis from prostate and breast cancers and a very low percentage of patients (∼20%) survive for more than five years after bone marrow cancer is diagnosed due to the vicious cycle [13] . Since the bone microenvironment is a fertile soil to the development of this type of cancer, it is crucial to better understand the interactions between osteoclasts, osteoblasts, bone density and the tumor. In [11] a model to represent the microenvironment interactions between osteoclasts, osteoblasts and the bone mass density was developed. A tumor growth model is proposed in [4] and the model of [11] was adapted to show the relations that the tumor has with the bone microenvironment. A recent research [10] employs continuous optimal control to deal with this disease and uses a classical PI controller to recover the bone mass density.
B. Paper Contributions and Structure
The main goal of this work is to develop a control and adaptive based framework to schedule a therapy to reduce the density of a cancer tumor. The time evolution of the tumor density T, is represented by a nonlinear function, that depends on the tumor density itself and on the drug effect, u. To discover which drug effect u, should be applied, the MPC algorithm is used in order to solve an optimization problem. For that sake, a quadratic cost function that weights the drug effect u and the error between the tumor density T and a reference signal T ref , is used. An exponential reference signal is used to generate smaller errors between T and T ref . The PK and the PD of a drug are modelled so that the drug dose is the manipulated variable to better traduce the reality.
Summarizing, a drug dose d (an impulse signal) will generate a drug concentration c given by its PK model, that in turn is going to produce a drug effect u, given its PD model. Since MPC computes an optimal drug effect u * , but only the drug dose d can be manipulated, it is necessary to find the optimal drug effect u * that corresponds to the optimal drug concentration c * . To do so, the inverse PD model is defined and used. To discover which drug dose d is going to generate a drug concentration c as close as possible to the optimal drug concentration c * , a controller with an asymptotic observer is designed (see Figure 1) . Note that the drug dose could be the number of pills or even the number of chemotherapy cycles. Since the therapy is not specified in this work, the drug dose d is dimensionless.
To find the tumor density model that best fits a patient, the Recursive Least Squares (RLS) method is used to learn the model parameters from data, in real time, yielding an adaptive MPC algorithm. The framework developed is used with the model of [4] to suppress the tumor and to break the vicious cycle. The bone mass density recover is enhanced using a classical discrete PI algorithm.
After this introduction where are presented the motivation, the literature review and the main contribution, the paper is structured as follows: the mathematical models of PK, PD and drug resistance are defined as well as the tumor density time variation. Then, the MPC is formulated. Some MPC performance characteristics are studied and the developed framework is used to eliminate a bone marrow tumor. To recover to an healthy bone mass density, a discrete PI controller is used.
II. MODELS A. Pharmacodynamical model
The pharmacodynamical model (Figure 2) is composed of the PK, PD, and the drug resistance models, and aims to bring a real clinical therapy to the simulation. Figure 2 shows the block diagram composed of these models. The PK control is designed as in Figures 3 and 4 . 
1) PK model:
The PK model of a drug is represented by a linear and time invariant system with 2 real poles and unitary static gain where s is the complex frequency in rad · s −1 and p 1,2 ∈ + are the poles magnitude. This model relates the drug concentration c in the bloodstream as a function of time t with the therapy dose administered. Figure 5 shows the impulse response of the PK model. Consider now the equivalent state space representation of the transfer function (1), represented by matrices A, B and C in the model
where x ∈ 2 is the state and y is the blood drug concentration. This system is fully controllable and observable and thus a controller with an asymptotic observer can be designed to discover the optimal drug dose d. Let the system dynamics with a controller and a observer be given by
where K and L are gain vectors that may be computed using a pole placement technique. The closed loop system can be defined, in an equivalent way, by the following new matrices
The discrete response of the PK model with the controller and the asymptotic observer is given by the response for non-homogeneous systems, that is composed of the solution of the homogeneous equation and the input signal, using the superposition theorem [15] . With the system defined by matrices (4), the drug concentration evolution in discrete time, for Dirac input signals d(k), is given by
where ∆ is the sampling time.
2) PD model: The PD of a drug is represented by the Hill equation, assumed to be a static nonlinear relation given by
where c 50 ∈ + is the drug concentration value for which the drug effect is half of the maximum drug effect. It is assumed that c 50 may vary in time depending on the resistance model explained below. The PD model has an horizontal asymptote when the drug concentration tends to infinity, meaning that when the drug concentration increases, the drug effect tends to saturate. Therefore the PD model is normalized to vary between u min = 0 (no drug effect) until u max = 1 (maximum drug effect). The drug effect variation as a function of the drug concentration is presented in Figure 6 . 3) Drug resistance model: If the drug concentration c is below a given threshold c lim , only weak cells are killed. The cells reproduced are resistant to that amount of drug concentration. This phenomenon is called drug resistance ( Figure 7 ). Let r(k) be the drug resistance level at time k
where δ is the sampling interval and c lim the limit above which no resistance to the drug is developed. When drug resistance is developed by the body, an higher drug concentration c is needed to perform the same drug effect u. This can be done by increasing the c 50 parameter proportionally to the drug resistance level [12] . Let c 50 be affected by the drug resistance r as follows
where c 50 (0) is the initial value of the c 50 parameter and K r ∈ + 0 is a parameter related to the ability of the disease to develop resistance to the drug. In Figure 2 , the block diagram R is composed by equations (7) and (8). To finish the explanation of the Figure 2 block diagram, the inverse pharmacodynamics model P D −1 is the function that gives drug concentration values as a function of the drug effect. The transposed graph of the P D −1 model is shown in Figure 6 . Although it has been concluded that the drug effect u will vary between u min = 0 and u max = 1, the inverse pharmacodynamics model is not defined when u = 1 (the corresponding drug concentration value would be infinity) and for that reason, from now on, the u max is limited to 99% of the maximum drug effect (u max = 0.99) for both P D and P D −1 models.
B. Bone microenvironment model with tumor and drug treatment dynamics 1) Tumor growth model: It is assumed that a cell-kill drug is administered to the patient to diminishing the tumor density. Thus, the tumor growth model used in [4] is slightly changed to a more realistic one [5] . Consider that the tumor density variation is given as a function of continuous time t by T (t)
where a ∈ R + is a parameter related to the tumor growth rate, b ∈ R + 0 is the tumor sensitivity to the drug, η ∈ R + is the plateau level, T ∈]0, η[ is the tumor density and u 2 ∈ R + 0 is the tumor cell kill drug effect. In the absence of treatment, model (9) leads to an S-shaped growth, with η being an horizontal asymptote. Although the drug effect u causes the tumor growth to decrease, when T becomes small, the effect of u also decreases and there is no danger that T is driven to meaningless negative values.
2) Bone microenvironment model: Consider the following nonlinear model, presented in [4] , where C(t) and B(t) represent, respectively, osteoclasts and osteoblasts activity, and Z(t) represents the bone mass density, as a functions of continuous time ṫ
where g •• , r •• , α • , β • and k • are bone microenvironment model parameters, and C and B are the mean value of osteoclasts and osteoblasts function [11] . The variable u 1 represents the osteoblasts recovery drug effect. Since the control algorithms used operate in discrete time, models (9) and (10) are approximated using the 4 th order Runge−Kutta method, with step size h. Thereafter, consider y(k) as the discrete version of T (t).
III. RECURSIVE LEASTS SQUARES METHOD
The adaptive MPC strategy is obtained by using the RLS method to estimate the model parameters. The new estimate of the parametersθ(k+1) is found as a function of the previous estimateθ(k), the system input u(k) and system output y(k + 1) [17] . Let the method be defined bŷ
where K g is the Kalman gain, P is the covariance matrix and φ is the vector with the model dependent variables such that y(k + 1) = φ(k) T θ. By applying the 4 th order Runge-Kutta method to discretize the Gompertz model (9), the result is an accurate discrete model. However the model is nonlinear in the parameters. Thus, consider for the purpose of parameter estimation that the Gompertz model (9) is discretized by the 1 st order Euler method. The discrete Gompertz model with this last method is given by
where h ∈ + is the discretization step size and rewriting in the RLS notation
the method is fully described, assuming that the plateau level η is well known.
As MPC algorithm and RLS method use different discretization methods to obtain a discrete Gompertz model, it is expected that the estimated parameters with the Euler method have a deviation from the real ones.
IV. NONLINEAR MPC OF TUMOR GROWTH

A. MPC formalization
At time k it is desired to discover which value should u 2 (k) be to reduce the tumor density. This is done by solving the following constrained optimization problem in a receding horizon strategy
where U min = u min · 1 and U max = u max · 1 are the constant constraint vectors with the same dimension as U . The cost function J is the quadratic cost function defined as
where Y k+1 is the predicted output vector
N is the prediction horizon and ρ ∈ + is a tuning parameter. The reference signal vector Y * k+1 that Y k+1 should follow is given by
and U k is the virtual inputs control vector
With an initial condition y(0) the problem (14) solution is
where the inequality is to be taken elementwise. Note that only the first element of U * k , u * 2 (k), is actually applied to the system. The same procedure is repeated at time k + 1, in a receding horizon strategy, to consider the system output feedback, which gives a level of robustness to the controller. To solve the optimization problem (14) , the fmincon MAT-LAB function is used. This function uses the quasi-Newton algorithm, which needs an initial estimate of the solution U * for every time k. The first estimate of U * , U 0 (0) is a vector of ones, with length N . Therapeutically, this estimate is equivalent to the worst case scenario where the drug effect is set to the maximum admissible value in all the prediction horizon. Although the choice of U 0 (0) influence the solution of (19), the initialization U 0 (0) is not crucial to solve the optimization problem as will be seen below. The next estimates are given by
for k > 0.
B. MPC performance and features
In order to assess the dependence of the MPC performance on the parameters that configure it, some simulation results are presented thereafter, in Figure 9 to 13, with the RLS estimator turned off. Let "5% rise time", be the time that y(k) takes to reach 5% of the difference between the initial tumor density y(0) and the equilibrium tumor density y(+∞), and the "Ratio T eq /T ∞ " be the offset between the equilibrium of y, T eq , and the reference signal equilibrium, called T ∞ . Those two performance characteristics are studied as a functions of the maximum drug effect u max and the optimization parameter ρ. The experiment is to follow an exponential reference given by
with initial tumor density y(0) = 97.5, T ∞ = 10 and where λ ∈ + is a parameter that defines how quickly the reference signal varies. The exponential reference signal starts in accordance with y(0). Figure 9 shows the typical result of simulating the block diagram of Figure 8 . The tumor density is tracking the reference signal and the system reaches the equilibrium in approximately 5 weeks of therapy. The value chosen to the step size h makes the controller to compute the system input in a daily base. The Figure 9 bottom graph shows the daily drug dose that must be administered to the patient.
To study the performance of the controller, the block diagram of Figure 8 is simulated for different u max with a fixed ρ and vice-versa. Figure 10 shows that as u max decreases, the system response y is slower. However, when u max is small, MPC cannot drive y to T ∞ , even if the simulation time is increased. As seen, u max is set to 1 and by inspection this value allows the MPC to drive y to T ∞ in an admissible time with no offset. Figure 11 shows that as ρ increases, the smaller is the band width and the slower the system response will be. Furthermore, more robustness is given to the system because the high frequency dynamics is attenuated. Moreover, by increasing p, the bigger the offset will be. Two other important characteristics to study are the relation between the simulation cost and simulation time as a function of the prediction horizon, N . When analysing the cost as a function of the prediction horizon, two cases were considered: in Test 1, the MPC tumor density model has no parameter errors, while in Test 2 MPC tumor density model has ±20% parameter errors. Let J be the cost that evaluates all the experience, with D samples, defined as T and T ref does not vanish in Test 2, due to the differences between the model that MPC knows and the real system behaviour. There is no specific rule to choose the best number of predictors N . Although, there is a rule of thumb that suggests that the chosen N should be after the cost curve knee, because more predictors will cause a very small decrease of the cost. For the Test 1 case, the cost curve knee is at N = 2, which means that any N > 2 is probably a good choice (for the Test 2 case, the cost curve knee is approximately at N = 5). However, big values of N does not mean that the cost J is reduced proportionally. It is clear that when N increase, the variation of J is almost null. Furthermore, when N increases, the simulation time increases exponentially (Figure 12) . Thus, the prediction horizon N was set to 7. Since the algorithm step size h is expressed in days, this prediction horizon value means that MPC is observing one week in the future. Concluding, there is no significant difference in the simulation time between the two tests, which is admissible, since MPC has to make exactly the same computations for both tests.
The initialization of the solution to the optimization problem (19), U 0 (0), was chosen to be a vector of ones, representing the worst case, a non optimal therapy where the drug effect is always at its maximum value. Besides the biological interpretation of this choice, any value for this vector will lead to the same drug effect therapy and consequently the same system response. Figure 13 shows the system input and output for four different U 0 (0). Although the system input and output are different in the first weeks, all the system inputs converges to the same result, showing that the value of the initialization of the optimization problem is not crucial.
V. BONE MASS RECOVERY
In this section, the framework represented by Figure 8 is used with the model determined in [4] that is represented by the block diagram of the Figure 14 , to decrease the tumor density and to recover bone mass. Two time instants were defined: k 1 is the same as in [4] and represents the beginning of both treatments (tumor cell kill drug and osteoblasts regulator drug), and k 2 is where it is considered that the tumor is eliminated. For the purpose of recovering the bone mass density, a discrete PI controller with forward Euler integrator is used to compute the drug effect u 1 , assumed to be the manipulated variable. The controller is given by the following difference equation [18] 
where
and e(k) is the error between the osteoblasts reference signal and the output at time k. The approach is the following: between k 1 and k 2 both osteoblasts regulator drug and the tumor cell kill drug are administered to the patient, and after k 2 only the osteoblasts regulator drug is still administered. This decision is based on [13] that suggests that, to break the vicious cycle, the osteoclasts number must return to a normal value, so that excessive bone resorption stops making the tumor to not spread to other sites. Figure 15 shows the tumor growth model parameters estimation since k = k 1 . It is visible that the estimate converges in approximately 10 days. Althoughâ is close to the real value,b shows an error when compared to the real one, which is admissible due to the difference between the Euler and the Runge-Kutta discretization methods. It is acceptable to consider, for instance, that this difference is a result of an error on the sensors that measure the tumor density. Figures 18 and  19 show that, between k = 0 and k 1 , where no drugs were applied, the tumor density starts to increase, deregulating the balance between osteoclasts and osteoblasts, and consequently the bone mass density starts to decrease from the steady state.
The presence of the vicious cycle is also evident. The amplitude of osteoclasts and osteoblasts dynamics is changed. Osteoclasts increase in number, destroying more bone than the one that is created and also the period of oscillations is affected. Between k 1 and k 2 , where both drugs are applied, the tumor density decreases until the tumor is considered to be extinct (T < 2%) following a reference signal given by (21) and osteoclasts and osteoblasts balance starts to recover as also does the bone mass density. After k 2 , where only the osteoblasts regulator drug is active, bone mass density continues to recover until it reaches the steady stateZ = 100. The variation of the cell kill drug concentration c, the c 50 parameter and the drug resistance level r are shown in Figure  17 . Those graphs only have meaning when the tumor cell kill drug therapy is on, this being the reason why those measures were set to 0 after k 2 . 
VI. CONCLUSIONS
The combination of both MPC and RLS methods provides an adaptive optimization solver, applied here to the treatment of bone marrow cancer. Optimizing the therapy can be formulated as a control problem whose solution provides a drug dose schedule. This open-loop solution can be transformed into a feedback control law, with all the inherent advantages, by using the receding horizon strategy. In the simulations presented, MPC can drive the tumor density to low values, interrupting the vicious cycle and stopping the tumor from spreading to other organs.
The MPC also shows to be a powerful and robust tool. When considering errors between the system model and the actual system output as well as when using different methods to discretize the Gompertz model, the controller still drives the tumor density to the desirable reference values. Adding a therapy to regulate the osteoblasts activity and consequently to recover an healthy bone mass density, this framework provides an optimal drug dose to the patient, killing the tumor in approximately 2 years and recovering a normal bone mass density in 5 years, assuming model validity.
According to [13] and as seen in this work, the bone marrow cancer has the ability to deregulate the healthy balance between the osteoclasts and osteoblasts in order to accelerate the bone resorption process which, in turn, promote further tumor growth, known as the vicious cycle. Thus, the tumor growth model presented in [4] should be review in order to model the interference that the osteoclasts and osteoblasts activity have in the tumor growth dynamics.
For future work, it may be interesting to adapt the pharmacodynamical model (PK, PD and drug resistance) to real data. Furthermore, the drug toxicity effect associated with huge values of drug concentration also have to be considered. Finally, it was assumed that it is possible to have full control on the osteoblasts recovery drug effect u 1 which is not admissible. A more realistic therapy must be considered by taking into account the pharmacodynamical model of this drug. Although the above aspects are essential when modelling a realistic therapy of cancer, they exceed the objective of this paper that was circumscribed to show how MPC can be applied together with the pharmacodynamical models in an adaptive strategy, to kill a cancer tumor.
